A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given
together with Temozolomide (chemotherapy) in treating patients with solid tumors, including
metastatic melanoma (MM), BRCA deficient breast, ovarian, primary peritoneal, or fallopian
tube cancer, and hepatocellular carcinoma (HCC).